334932-13-7

Basic information

• Product Name: BOC-(+/-)-CIS-3-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID
• Synonyms: 3-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID;BOC-(+/-)-CIS-3-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID;BOC-CIS-3-AMINOCYCLOHEXANE CARBOXYLIC ACID;BOC-CIS-1,3-AMINOCYCLOHEXANE CARBOXYLIC ACID;BOC-1,3-CIS-ACHC-OH;CIS-3-(BOC-AMINO)CYCLOHEXANECARBOXYLIC ACID;CIS-3-TERT-BUTOXYCARBONYLAMINOCYCLOHEXANECARBOXYLIC ACID;(R,S)-CIS-1-(TERT-BUTYLOXYCARBONYL-AMINO)-CYCLOHEXYL-3-CARBOXYLIC ACID
• CAS NO: 334932-13-7
• Molecular Formula: C₁₂H₂₁NO₄
• Molecular Weight: 243.3
• EINECS: 200-528-9
• Product Categories: N-BOC
• Mol File: 334932-13-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 396.7±31.0 °C(Predicted)
• Appearance: /
• Density: 1.12±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 4.77±0.13(Predicted)
• Water Solubility: Slightly soluble in water (2.1 g/L at 25°C).
• CAS DataBase Reference: BOC-(+/-)-CIS-3-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-(+/-)-CIS-3-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID(334932-13-7)
• EPA Substance Registry System: BOC-(+/-)-CIS-3-AMINOCYCLOHEXANE-1-CARBOXYLIC ACID(334932-13-7)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 334932-13-7(Hazardous Substances Data)

Usage

Uses

3-(Boc-amino)cyclohexanecarboxylic acid is used as pharmaceutical intermediate.

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 16636-51-4 3-aminocyclohexanecarboxylic acid 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 222530-34-9 (1S,3R)-3-((tert-butoxycarbonyl)amino)cyclo hexane-1-carboxylic acid 
• 478831-97-9 3-amino-N,N-dibenzylcyclohexanecarboxamide monohydrochloride 
• 478832-00-7 3-[(dibenzylamino)methyl]cyclohexanamine 
• 920966-16-1 tert-butyl [3-(hydroxymethyl)cyclohexyl]carbamate 
• 1607590-83-9 3-(3-{2-[(1R)-1-hydroxyethyl]-1H-imidazo[4,5-d]thieno[3,2-b]pyridin-1-yl}cyclohexyl)propanenitrile 
• 1607590-88-4 3-{3-[(6-aminothieno[3,2-b]pyridin-7-yl)amino]cyclohexyl}propanenitrile 
• 1607590-87-3 3-{3-[(6-nitrothieno[3,2-b]pyridin-7-yl)amino]cyclohexyl}acrylonitrile 
• 1607590-86-2 3-(3-aminocyclohexyl)acrylonitrile hydrochloride 
• 1607590-85-1 tert-butyl {3-[2-cyanovinyl]cyclohexyl}carbamate 
• 1607590-84-0 tert-butyl (3-formylcyclohexyl)carbamate 

Relevant articles and documents

Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof

The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.

ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF

The present invention relates to heterocyclic compounds of Formula I useful as anti-infective agents. The present invention further relates to a method of treating an infection by administering such compounds, and to pharmaceutical compositions comprising such compounds.

NOVEL SEH INHIBITORS AND THEIR USE

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R4, R5, R6, A, B, Y, Z, n, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.